Corteva Inc

Latest Results (15.07.2026):

Corteva Inc reported results for the first quarter of 2026 (1Q 2026). Net sales rose to $4.90 billion (up 11% vs. 1Q 2025; organic +7%), GAAP income from continuing operations was $725 million with GAAP diluted EPS of $1.07, and non‑GAAP Operating EBITDA was $1.44 billion with Operating EPS of $1.50. The company reaffirmed full‑year 2026 guidance and reported continued margin expansion across Seed and Crop Protection.

Top-line and earnings

Net sales: $4.905B (+11% YoY; organic $4.726B, +7%). GAAP income from continuing operations: $725M; GAAP diluted EPS: $1.07. Non‑GAAP Operating EBITDA: $1.438B (+21% YoY) and Operating EPS: $1.50 (+33% YoY).

Segment performance — Seed

Seed net sales: $3.023B (+12% YoY; organic +9%). Drivers: volume +6%, price/mix +3%, favorable currency. Seed operating EBITDA: $1.034B (+23% YoY) with ~310 bps margin expansion versus prior year.

Segment performance — Crop Protection

Crop Protection net sales: $1.882B (+10% YoY; organic +4%). Drivers: volume +6% (new products, spinosyns), price down ~2% in some markets. Crop Protection operating EBITDA: $434M (+15% YoY) and ~100 bps margin improvement.

Regional results

Net sales by region (1Q 2026): North America $2,439M (+10%, organic +10%); EMEA $1,655M (+12%, organic +4%); Latin America $506M (+14%, organic +4%); Asia Pacific $305M (+6%, organic +5%).

Guidance, capital allocation and notable items

Full‑year 2026 reaffirmed: Operating EBITDA $4.0–$4.2B and Operating EPS $3.45–$3.70. Planned share repurchases of ~$500M in H1 2026. Company expects ~ $350M of one‑time separation costs and included $50M of net dis‑synergies in 2026 guidance; restructuring charges for Crop Protection network expected ~$80–90M in 2026.

Separation progress

Corteva remains on track for the planned separation (company communications reference second half of 2026 and an overall plan tied to late‑2026 milestones and investor events). Announced Vylor as the future seed/genetics company name, named executives, filed an initial Form 10, and outlined timing for further filings, credit reviews and board appointments.

Cash flow & balance sheet items

Operating cash flow was negative $(2.885)B for continuing operations in 1Q 2026, driven mainly by increases in accounts receivable and declines in deferred revenue; cash and cash equivalents were $1.964B at March 31, 2026. The Board approved a discretionary U.S. pension contribution of ~ $1.5B to be made on or before July 31, 2026.